ERA Congress: Long-Term Data Show Zigakibart’s Efficacy in IgA Nephropathy
New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy...